Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ADVM | Adverum Biotechnologies, Inc.

Index- P/E- EPS (ttm)-1.33 Insider Own1.20% Shs Outstand100.77M Perf Week7.69%
Market Cap169.61M Forward P/E- EPS next Y-1.00 Insider Trans8.39% Shs Float96.21M Perf Month0.60%
Income-133.40M PEG- EPS next Q-0.32 Inst Own64.50% Short Float / Ratio1.16% / 2.43 Perf Quarter26.32%
Sales3.60M P/S47.11 EPS this Y-4.90% Inst Trans0.58% Short Interest1.11M Perf Half Y124.63%
Book/sh1.30 P/B1.29 EPS next Y16.70% ROA-46.10% Target Price4.25 Perf Year60.00%
Cash/sh1.40 P/C1.20 EPS next 5Y- ROE-78.60% 52W Range0.53 - 2.34 Perf YTD189.91%
Dividend- P/FCF- EPS past 5Y-8.10% ROI- 52W High-28.21% Beta0.82
Dividend %- Quick Ratio3.30 Sales past 5Y- Gross Margin- 52W Low216.38% ATR0.13
Employees123 Current Ratio3.30 Sales Q/Q- Oper. Margin- RSI (14)50.36 Volatility11.51% 7.53%
OptionableYes Debt/Eq0.00 EPS Q/Q29.30% Profit Margin- Rel Volume0.65 Prev Close1.55
ShortableYes LT Debt/Eq0.00 EarningsAug 10 AMC Payout- Avg Volume457.76K Price1.68
Recom2.00 SMA200.60% SMA50-7.90% SMA20050.02% Volume296,355 Change8.39%
Date Action Analyst Rating Change Price Target Change
Jul-07-22Upgrade Truist Hold → Buy $4
Jul-23-21Downgrade Cantor Fitzgerald Overweight → Neutral
May-03-21Downgrade SVB Leerink Outperform → Mkt Perform $5
Apr-29-21Downgrade Truist Buy → Hold $30 → $9
Apr-29-21Downgrade RBC Capital Mkts Outperform → Sector Perform $6
Apr-29-21Downgrade Chardan Capital Markets Buy → Neutral $5
Dec-16-20Initiated UBS Neutral $13
Nov-12-20Upgrade Raymond James Underperform → Mkt Perform
Jun-26-20Downgrade Raymond James Mkt Perform → Underperform
May-13-20Initiated RBC Capital Mkts Outperform $24
Sep-21-23 04:05PM
Sep-05-23 04:05PM
Aug-21-23 04:05PM
Aug-14-23 08:00AM
Aug-10-23 04:20PM
04:05PM Loading…
Jun-12-23 08:00AM
Jun-02-23 08:00AM
May-25-23 06:30AM
May-18-23 09:00AM
May-11-23 04:47PM
May-10-23 04:05PM
May-02-23 04:30PM
01:00PM Loading…
Apr-23-23 01:00PM
Apr-21-23 06:03AM
Apr-18-23 08:00AM
Apr-17-23 04:05PM
Apr-04-23 09:40AM
Mar-30-23 04:05PM
Mar-02-23 10:23AM
Feb-27-23 04:05PM
Jan-18-23 04:05PM
Dec-06-22 04:05PM
Nov-10-22 04:05PM
Nov-04-22 12:08PM
Oct-27-22 04:05PM
Sep-30-22 04:45PM
Sep-27-22 04:05PM
04:05PM Loading…
Sep-23-22 04:05PM
Sep-15-22 05:19PM
Sep-14-22 08:00AM
Sep-08-22 04:05PM
Aug-26-22 04:05PM
Aug-11-22 04:05PM
Aug-10-22 04:05PM
Aug-01-22 04:05PM
Jul-25-22 07:16AM
Jul-15-22 09:52AM
Jul-08-22 08:00AM
Jul-07-22 05:14PM
Jul-06-22 04:05PM
Jun-24-22 08:00AM
Jun-09-22 08:00AM
Jun-02-22 04:05PM
May-19-22 08:00AM
May-18-22 08:11AM
May-17-22 04:05PM
May-12-22 04:05PM
May-11-22 02:51PM
May-09-22 04:05PM
May-02-22 04:30PM
May-01-22 02:15PM
Apr-19-22 06:00PM
Apr-07-22 02:50PM
Apr-06-22 04:05PM
Mar-29-22 04:05PM
Mar-17-22 04:05PM
Mar-02-22 12:11PM
Feb-28-22 08:00AM
Feb-15-22 04:22AM
Feb-07-22 04:05PM
Jan-06-22 04:05PM
Jan-04-22 08:00AM
Jan-01-22 06:02AM
Dec-21-21 12:42PM
Dec-06-21 09:00AM
Nov-30-21 10:25AM
Nov-17-21 04:51AM
Nov-04-21 04:05PM
Oct-09-21 11:17AM
Oct-05-21 05:17AM
Oct-04-21 02:31PM
Oct-03-21 08:14AM
Oct-01-21 04:00PM
Sep-27-21 09:00AM
Aug-23-21 09:00AM
Aug-19-21 07:05AM
Aug-06-21 10:19AM
Aug-05-21 04:05PM
Jul-22-21 04:05PM
Jul-19-21 02:49PM
Jul-01-21 08:00AM
Jun-28-21 12:00PM
Jun-24-21 04:05PM
Jun-21-21 01:22AM
Jun-07-21 10:00AM
Jun-01-21 08:00AM
Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Seyedkazemi SetarehChief Development OfficerSep 15Sale1.526,2019,42947,674Sep 18 06:54 PM
Rubinstein Linda MChief Financial OfficerJun 07Buy1.45100,000145,490100,000Jun 09 04:26 PM
Fischer LaurentCEO, President and DirectorMar 15Sale0.7841,23932,232692,141Mar 17 06:01 PM
Soparkar PeterChief Operating OfficerMar 15Sale0.7813,36010,442265,891Mar 17 06:02 PM
Riley BrigitChief Scientific OfficerMar 15Sale0.787,2995,705117,435Mar 17 06:02 PM